{"id":4068,"date":"2026-11-03T07:00:00","date_gmt":"2026-11-03T11:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4068"},"modified":"2026-11-04T21:49:27","modified_gmt":"2026-11-05T01:49:27","slug":"ser-155-transplant-infection-data-enter-peer-reviewed-record","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4068","title":{"rendered":"SER-155 Transplant Infection Data Enter Peer Reviewed Record"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"384\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261104_Seres_Therapeutics_Therapeutic_Indications-768x384.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4076\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261104_Seres_Therapeutics_Therapeutic_Indications-768x384.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261104_Seres_Therapeutics_Therapeutic_Indications-300x150.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261104_Seres_Therapeutics_Therapeutic_Indications-1024x512.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261104_Seres_Therapeutics_Therapeutic_Indications-1536x768.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261104_Seres_Therapeutics_Therapeutic_Indications.png 1774w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Seres Therapeutics<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Peer-reviewed publication (Nature Medicine)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Live biotherapeutic (microbiome)<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>SER-155<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>Gut pathogen expansion and mucosal barrier<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Bloodstream infection after allogeneic HCT<\/p>\n<h4>Summary<\/h4>\n<p>A Nature Medicine Phase 1b paper published online November 3 reports fewer bloodstream infections through day 100 after allogeneic hematopoietic cell transplantation with oral SER-155 than placebo in its randomized cohort. This peer-reviewed publication is a 36-hour-window recovery, not a new Phase 2 readout.<\/p>\n<p>The trial combined an open-label pharmacology cohort with a randomized, double-blind, placebo-controlled cohort. In the latter, bloodstream infections occurred in 10% on SER-155 versus 42.9% on placebo (p=0.0423); systemic antibiotic exposure averaged 9.2 versus 21.1 days (p=0.0494). The company reported strain engraftment and no treatment-related serious adverse events. The randomized cohort comprised 20 active and 14 placebo participants.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> a cultivated microbial consortium may reduce gut pathogen expansion and preserve barrier integrity after transplant conditioning, reducing translocation into blood. The infection and biomarker patterns support this. Counterargument: the infection endpoint was exploratory in a small Phase 1b cohort, with few events and potentially unstable estimates.<\/p>\n<p><strong>Interpretation B:<\/strong> an imbalance in conditioning, baseline microbiome, antimicrobial use, or transplant risk could explain part of the observed difference. Randomization and blinded assessment mitigate but do not eliminate this concern at n=34. A larger powered trial with stratified transplant and antibiotic factors, adjudicated infections, mechanistic sampling, graft-versus-host disease and survival outcomes would test the claim.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Seres develops cultivated live biotherapeutics. SER-155 is an oral multi-strain bacterial product intended to support mucosal barrier integrity and limit pathogen outgrowth during allogeneic hematopoietic cell transplantation for blood cancers.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Microbiome-directed infection prevention remains investigational.<\/li>\n<li>The 77% relative reduction derives from 10% versus 42.9%, with wide uncertainty expected from small denominators.<\/li>\n<li>FDA Breakthrough and Fast Track designations are prior regulatory status, not approval.<\/li>\n<li>Seres says Phase 2 start is dependent on funding.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>A clinically relevant randomized signal and biological coherence justify a confirmatory study. The result is not yet a basis for generalizing across donor types, conditioning regimens, or transplant centers.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: cautiously positive for clinical hypothesis. Confidence in Facts: high for publication and reported counts. Confidence in Interpretation: moderate-low because the study was small and not powered for definitive efficacy.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A Nature Medicine Phase 1b paper published online November 3 reports fewer bloodstream infections through day 100 after allogeneic hematopoietic cell transplantation with oral SER-155 than placebo in its randomized cohort. This peer-reviewed publication&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4076,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1365,1364,1363],"class_list":["post-4068","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-allogeneic-transplant","tag-ser-155","tag-seres-therapeutics"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4068","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4068"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4068\/revisions"}],"predecessor-version":[{"id":4086,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4068\/revisions\/4086"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4076"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4068"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4068"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4068"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}